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Abstract  
BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of 
hematopoietic stem cells. It is characterized at the cytogenetic level by Philadelphia (ph) 
chromosome and at the molecular level by the BCR/ABL gene rearrangement. Bone marrow 
derived mesenchymal stem cells (MSCs) are pluripotent stem cells that can differentiate into 
several mesenchymal tissues.  
AIM: To observe the biological characteristics of MSCS from CML patients and to determine 
whether MSCs harbor the abnormal BCR/ABL translocation similar to CML bone marrow cells.  
SUBJECTS AND METHODS: Characterized MSCs were isolated from 12 newly diagnosed 
Philadelphia positive untreated CML patients.  
RESULTS: MSCs can be readily isolated from CML marrow and exhibit major expansion. Flow 
cytometry analysis revealed the typical MSC phenotype. Moreover; MSCs do not harbor the 
BCR/ABL translocation confirmed by karyotype and real time PCR.  
CONCLUSION: MSCs from CML patients express the typical MSC phenotype; and do not express 
the BCR/ABL gene. Since; MSCs are able to support engraftment of hematopoietic stem cells in 
stem cell transplantation(SCT) as well as suppress alloreactive T cells causing graft versus –host 
disease, this current study provides evidence that in a SCT setting of CML patients, autologous 
MSCs could be a source of stem cell support in future cell therapy applications.    
 
 
 
 
 
 
 
Introduction 
 
Bone marrow (BM) is composed of at least 
two systems, the hematopoietic tissue proper and the 
stroma. Mesenchymal stem cells (MSCs) are 
important constituents of this microenvironment and 
are characterized as adult, non-hematopoietic stem 
cells (HSCs) which , after an adequate stimulus, can 
differentiate morphologically and functionally into 
different cell lines including the stroma, which gives 
support to hematopoiesis, adipocytes, chondrocytes, 
myocytes, astrocytes, tenocytes, and hepatocytes [1]. 
Chronic myeloid leukemia is a clonal 
myeloproliferative disorder of hematopoietic stem 
cells. It is characterized at the molecular level by 
BCR/ABL gene re-arrangement [2]. This 
rearrangement results in a shortened chromosome 
22, designated the Philadelphia (Ph) chromosome [3].  
Previous studies have suggested that CML 
stem cells might be more primitive stem cells than 
multipotent HSCs when the BCR/ABL fusion gene in 
haemangioblastic-like cells have been identified [4] 
while other studies found the BCR/ABL fusion gene in 
even more primitive progenitor cells defined as Flk1
+
, 
CD31
-
, CD34
- 
[5]. 
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All these findings raised the question whether 
the BCR/ABL fusion gene can also be found in MSCs 
in patients with CML. Since Ph+biphenotypic leukemia 
may arise from even more immature stem cells than 
CML, the potential relation of such stem cells to MSCs 
would also be of interest. In fact, whereas some 
recent data suggest that MSCs in chronic phase CML 
may not display clonal markers of CML, the more 
primitive variants of Ph+ neoplasms have not been 
investigated for such a relationship so far [6]. 
CML marrow is an abundant source of MSCs 
not to be involved by the malignant process of CML. 
Furthermore, these MSCs from a CML patient could 
support in vitro cord blood expansion as those MSCs 
from a normal donor [2]. 
Allogeneic stem cell transplantation (allo-
SCT) is the only curative treatment for CML as well as 
many hematological malignancies and other 
immunohematopoietic disorders [7]. 
According to recent studies [8] MSCs do not 
express the BCR/ABL gene so compare to allogeneic 
MSCs, autologous MSCs from patients needed cell- 
based therapy may be an ideal alternative stem cell 
source. However, characteristics of MSCs from a 
disease state are poorly understood [9]. 
The aim of this work is isolation and 
characterization of MSCs from CML patients and 
demonstration of whether MSCs from CML patients 
harbor the abnormal Ph chromosome, since 
autologous Philadelphia negative MSCs could be a 
source of stem cell support in future cell therapy 
applications. 
 
 
Subjects and Methods 
 
This study has been approved by the ethical 
comity of Cairo University and National Research 
Center .The study involved fifteen patients admitted to 
National Institute of Cancer with newly diagnosed 
Ph+ve CML as verified by karyotyping and FISH of 
their bone marrow aspirate. After informed consent 
had been obtained from all patients, 2 ml heparinized 
bone marrow samples were obtained by bone marrow 
aspirate from iliac crest and were used for: 
 
Isolation and culture of BM derived MSC 
BM mononuclear cells were separated by 
density gradient centrifugation using Biocoll 
separating solution; density 1.077 g/ml (Biochrom 
AG). Briefly, 5 ml of heparinized BM cells were mixed 
with equal volume of Dulbecco’s modified Eagle’s 
Medium (DMEM) (Hyclone, Thermscientific) and 
layered slowly over the Biocoll then centrifuged at 
400xg for 20 min at room temperature. 
The mononuclear cells were collected from 
the interface and washed twice with DMEM containing 
10% fetal calf serum (FCS,Euroclone). Total cell count 
and viability were evaluated by 0.2% Trypan blue 
exclusion. 
A total of 1x10^6 cells/ml of BM mononuclear 
cells were cultured in DMEM complete medium 
supplemented with 10% fetal calf serum (FCS, 
Euroclon) to promote their optimal expansion, 1% 
antibiotic/antimicotic (Hyclone) was added to prevent 
bacterial and fungal infection. Cultures were kept then 
in suitable environmental conditions e.g. (37ᴼC in 
humidified 5% CO2 air incubator). 
On day 3 of culture, non-adherent cells were 
discarded and fresh medium was added. Media was 
changed twice/week. When adherent MSCs reach 80-
90% confluent, they were trypsinized by 0.25% trypsin 
EDTE (Hyclon), 5 min at 37ᴼC then washed twice with 
complete media and passaged for the next expansion 
[10]. 
 
Flow cytometry analysis of cultured BM 
derived MSCs 
Immunophenotyping of BM derived MSCs 
was done as follow [8]. At the end of the third 
passage, cells were trypisinized and adjusted to 
1x10^6 cells/ml. then 1x10^6 cells were incubated 
with 10 µL of monoclonal antibodies as determined 
from the manufacturer's recommendation: CD 105 PE 
(mesenchymal marker), and exclusion markers CD34 
FITC (hematopoietic stem cell marker) at 4ᴼc in the 
dark. As a control unstained cells were applied first to 
exclude the effect of autofluoresence of the cultured 
cells. After 20 min incubation, 2ml of PBS containing 
2% FCS solution were added to each tube of 
monoclonal treated cells. The mixtures were then 
centrifuged for 5 min at 2500 rpm followed by 
discarding the supernatant and resuspending cells in 
500µl PBS containing 2%FCS. Finally, cell 
immunophenotyping was performed using 
CYTOMICS FC 500 flow cytometer (Beckman coulter, 
FL, USA) and analyzed using CXP software version 
2.2. 
 
Karyotypic analysis of hMSCs 
Trypsinized MSC were washed twice with 
Hank’s balanced salt solution (Lonza). One to two 
millions of cells were cultured in 20% fetal bovine 
serum/RPMI -1640 (Hyclone) in CO2 incubator 
overnight. Cells were fixed with a mixture of glacial 
acetic acid and absolute methanol (1:3 by volume). 
Finally, metaphase cells were dropped onto 
microscope glass slides. Giemsa-Trypsin (GTG) 
banded chromosomes were prepared and analyzed. 
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Reverse transcriptase polymerase chain 
reaction (REALTIME PCR) 
Total cellular RNA was extracted from 
cultured MSCs using high pure RNA isolation kit 
(Roche cat NO.11 828 665 001), after cDNA synthesis 
(Roche transcriptor first strand cDNA synthesis kit 
cat.NO. 04 896 866 001), amplification of the fusion 
gene BCR-ABL & hybridization were performed using 
light cycler 2& Roche light cycler fast DNA master 
HybProbe (cat no.03 003 248 001). Amplification of 
the ABL gene as internal control was done for each 
sample. Expression of target gene measured relative 
to mean critical CT values of the house keeping gene. 
 
 
Results 
 
The present work included fifteen patients 
(n=15) with newly diagnosed Ph+ve CML as verified 
by karyotyping and FISH. Of the fifteen patients, nine 
(60%) were males and six (40%) were females. The 
age ranged between 34-55 years with a mean of 44.4 
± 6.8 years.  TLC ranged from (180 000-320 
000/mm
3
) with mean of 233.333 ± 45. 3. Individual 
and clinical data of patients are shown in Table 1.  
Table 1: Individual and clinical data of CML patients. 
Patient Sex Age TLC/mm
3
 
1 male 40 180,000 
2 female 43 210,000 
3 female 34 290,000 
4 male 35 190,000 
5 male 40 300,000 
6 female 43 230,000 
7 male 49 250.000 
8 male 50 180.000 
9 male 51 260,000 
10 male 50 320.000 
11 male 37 250.000 
12 female 39 180,000 
13 male 55 200,000 
14 female 48 240,000 
15 female 53 220,000 
 
A cytogenetic study by karyotyping and FISH 
analysis of bone marrow cells revealed the presence 
of the Ph chromosome in all patients. 
Table 2: Cytogenetic and molecular analysis of BM and BM- 
derived MSCs of CML patients. 
Patient 
CML 
stage 
Bone marrow cells 
Bone marrow derived 
MSCs 
Karyotype FISH Karyotyping RT - PCR 
1 Chronic 46xy 30%, 
46xy,t(9,22)(q34;q11) 70% 
Positive ……….. ……….. 
2 Chronic 46xx,t(9,22)(q34; q11) 100% Positive ………… ………… 
3 Chronic 46xx,t(9,22)(q34; q11) 100% Positive …………. ………… 
4 Chronic 46xy,t(9,22)(q34; q11) 100% Positive Negative Negative 
5 Chronic 46xy,t(9,22)(q34; q11) 100% Positive Negative Negative 
6 Chronic 46xx,t(9,22)(q34; q11) 100% Positive Negative Negative 
7 Chronic 46xy,t(9,22)(q34; q11) 100% Positive Negative Negative 
8 Chronic 46xy,t(9,22)(q34; q11) 100% Positive Negative Negative 
9 Chronic 46xy,t(9, 14,22)(q34; q22; 
q11)100% 
Positive Negative Negative 
10 Chronic 46 xy 20% 
46xy,t(9,22)(q34 q11) 80% 
Positive Negative Negative 
11 Chronic 46xy,t(9,22)(q34 q11) 100% Positive Negative Negative 
12 Chronic 46xx,t(9,22)(q34 q11) 100% Positive Negative Negative 
13 Chronic 46xy,t(9,22)(q34; q11) 100% Positive Negative Negative 
14 Chronic 46xx,t(9,22)(q34 q11) 100% Positive Negative Negative 
15 Chronic 46xx,t(9,22)(q34 q11) 100% Positive Negative Negative 
 
Isolation and expansion of BM derived MSCs 
From the 15 BM samples collected: Two 
samples (13.33%) were discarded due to 
contamination (sample 1 and 2). One sample (6.66%) 
showed few adherent spindle shaped cells, however, 
these cells failed to grow and expand in the culture 
conditions (sample 3).  Spindle like cells were 
expanded from 12 samples (80%), where confluence 
was reached after 3 weeks. Cells were then splitted 
using Trypsin EDTA and replated at a density of 5000 
cells/cmm and were maintained till the third passage. 
MSCs are characterized by: 1) Plastic adherence that 
resist washing while changing the media and 2) 
Spindle fibroblast like morphology under the inverted 
microscope. Images were captured with a digital 
camera as shown in Figure 1. 
 
Figure 1:  Bone Marrow derived MSCs under inverted microscope 
at different days of culture. (a) Day 0: mononuclear cells isolated 
from BM-MSCs, (b) Day 5: MSCs colony forming unit, (c) Day 10 
MSCs with some hematopoietic cells contamination, (d) Day 
18:spindle shaped MSCs with few contaminating hematopoietic 
cells, (e) Day 21 and  (f) Day 21 confluent growth 80-90%). 
 
Immunophenotyping 
The cells were positive for CD 105 (97%). No 
detectable contamination of hematopoietic cells was 
observed, as flow cytometry analysis was negative for 
markers of hematopoietic lineage CD34 (2.59%), as 
shown in Figure 2. 
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Figure 2: The immunophenotypic analysis of cultured hMSCs 
isolated from the bone marrow of CML patients. 
 
Ph chromosome assessment 
a) Karyotypic analysis of MSCs: Cultured 
MSCS showed no cytogenetic aberrations when 
analyzed with conventional chromosomal staining 
(Fig. 3, 4). 
 
Figure 3: The karyotype of cultured hMSCs isolated from the bone 
marrow of female CML patients show normal pattern. 
 
 
Figure 4: The karyotype of cultured hMSCs isolated from the bone 
marrow of male CML patients show normal pattern. 
Real Time Polymerase Chain Reaction 
Interpretation of real time PCR curves (Table 
3): 
Table 3:  Analysis of results (Light Cycler® 2.0 Instrument, 
Roche Master: Fast Start). 
BCR-ABL t(9;22) 
(sample) 
NTC Result 
No amplification Negative Negative 
Amplification signal Negative Positive for  BCR-ABL t(9;22) fusion transcripts 
Amplification signal Positive Contamination, repeat experiment 
 
In all of the twelve BM derived MSCs 
samples, negative control (NTC) showed no signal. 
 The provided standard row of cloned and 
purified DNA with concentrations in the range from 10
6 
 
copies/rxn to 10
1
 copies/rxn of both housekeeping 
gene (ABL1) and BCR-ABL t(9;22) fusion transcript 
DNA b2a2 had CPs between cycles 18 and 35 (as 
described by manufacturer's instructions). 
  The BCR-ABL t(9;22) fusion transcripts was 
not detected as shown in Figure 5. 
a) 
 
b) 
 
c) 
 
d) 
 
Figure 5: a) Target amplification curve of Standard BCR-ABL (blue 
line) compared to that of a male patient (green line). A flat green 
line indicating no BCR-ABL translocation compared with that of 
standard. b) Reference amplification curve of Standard ABL1 (red 
line) compared to the housekeeping gene ABL1 (grey line) of a 
male patient. Both crossing the negative control (blue line), 
indicating successfully amplified patient RNA. c) Target 
amplification curve of Standard BCR-ABL (blue line) compared to 
that of a female patient (green line). A flat green line indicating no 
BCR-ABL translocation compared with that of standard. d) 
Reference amplification curve of Standard ABL1 (red line) 
compared to the housekeeping gene ABL1 (grey line) of a female 
patient. Both crossing the negative control (pink line), indicating 
successfully amplified patient RNA. 
 
 
Discussion 
Chronic myeloid leukemia (CML) is a 
hematopoietic stem cells cancer driven by the BCR-
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ABL fusion protein that arises from translocation of 
chromosomes 9 and 22. Cytoreductive chemotherapy, 
such as busulfan and hydroxyurea was a mainstay of 
therapy to control WBC counts, however, it did not 
modify the progression of the disease to accelerated 
phase and blastic phase. Allogeneic BMT is the only 
known curative therapy for CML; however, treatment-
related mortality from infection, bleeding, and graft 
versus host disease, age, and availability of suitable 
donors limits the widespread use [11]. 
Mesenchymal stem cells are multipotent, 
which means that they are able to differentiate into 
several lineages. Together with hematopoietic stem 
cells and endothelial stem cells, the MSCs form the 
progenitor cells in the bone marrow. They can 
stimulate and differentiate the blood cells in the bone 
marrow due to production of growth factors and 
cytokines. MSCs are generally known from their target 
in tissue regeneration fields, however, the role of the 
MSCs in the development and progression of 
leukemia is still unknown [12]. MSCs have been found 
to suppress inflammation by inhibiting T cell 
proliferation, representing a novel treatment for graft –
versus host disease (GVHD). In addition, MSCs seem 
not to suppress the whole immune system but 
specifically a GVHD without impairment of the graft 
versus leukemia effect in leukemia patients [13]. 
In the present work we succeeded to isolate 
and expand MSCs from 80% of CML patients. The 
high homogeneity of MSCs in present study was 
consistent with [14, 15]. 
In the current study, adherent MSCs derived 
from bone marrow of CML patients gave rise to 
colonies and exhibited characteristic spindle-shaped 
morphology after 7 days and they reached 90% 
confluency after an average of 21 days. This was in 
line with study that described their CML derived MSCs 
by showing dense growth after a median of 7 days [6]. 
Then, cells started to grow out of highly proliferative 
centres and spread radiantly throughout the culture. 
These centres were only seen before the first passage 
and disappeared afterwards. 
In the present study immunophenotyping 
analysis of MSCs by flow cytometry show that MSCs 
were positive for CD105 and negative for the 
hematopoietic marker CD45. This was in accordance 
with [6, 8] who described isolated MSCs from CML 
patients to be highly positive for CD73, CD90 and 
CD105 and negative for CD34 and CD45. 
In our study, karyotyping analysis of MSCs 
showed absence of Philadelphia chromosome. We 
have also investigated the presence of BCR-ABL 
translocation in CML patients derived MSCs by Real 
time PCR. Real time PCR demonstrated that the 
BCR/ABL fusion gene was not present in bone 
marrow derived MSCs of CML patients despite its 
presence in the corresponding bone marrow cells. 
These findings were in agreement with [9, 12] who 
demonstrated that CML derived MSCs did not express 
BCR/ABL gene and Philadelphia chromosome and 
had not the ability to develop tumor in nude mice  
In contrast to our results [8] had characterized 
phenotypically and cytogenetically a population of 
MSCs isolated from BM of 5 Ph+ve untreated CML 
patients. They analyzed the BCR-ABL gene by fish in 
1513 nuclei. They only detected 0.01% (2/1513) BCR-
ABL positive MSCs. They referred the detection of 
these two BCR-ABL positive nuclei to the presence of 
hematopoietic contamination in the culture of these 
cells, possibly (CD14) BCR-ABL positive 
macrophages that grow adhering to MSC. 
Also it was in accordance with our results as 
their results suggested that cultured MSCs in patients 
with BCR-ABL positive CML do not harbor this 
specific translocation [6]. Apart from two samples that 
were positive for BCR-ABL when analyzed with a 
highly sensitive RT-PCR method typically used for 
detecting minimal residual disease CML patients. 
They suggested a contamination of the MSC 
population with hematopoietic cells, most likely 
macrophages as Fluorescence Activated Cell Sorting 
(FACS) analysis of these samples showed a small 
CD45 positive cell population  
Being in line with authors who described 
BCR-ABL positive macrophages contaminating in vitro 
cultures of stromal cells from BM of CML patients, 
Wὃhrer et al., 2007 showed that the abnormal stromal 
function in CML might in fact be due to the presence 
of BCR-ABL positive macrophages in the marrow 
microenvironment which may contribute to selective 
expansion of leukemic hematopoietic cells [16]. 
Tyrosine kinase (TK) inhibitor drugs 
specifically target BCR-ABL, the constitutively 
activated tyrosine kinase fusion protein and 
revolutionized treatment of CML [17]. 
Bone marrow transplantation was also used 
as initial treatment of CML before advent of Imatinib 
tyrosine kinase inhibitor, but in now rarely used, 
primarily for those who fail drug treatment (Kimura et 
al., 2006). Stem cell transplantation remains an option 
for those patients who rarely develop T3151 mutation 
[18], refractory cases to chemotherapy, Philadelphia 
negative CML & cases resistant to inhibitors [19]. 
MSCs are known to interact with HSCs and 
immune cells, and represent potential cellular therapy 
to enhance allogeneic hematopoietic engraftment and 
prevent GVHD. Co-culture of MSCs and HSCs could 
cause a significantly increase in CD34+ve cells [20]. 
MSCs negative for the malignant 
transformation could be an important tool used to 
alleviate GFHD. Lazarus et al., reported that 
autologous MSCs, derived from hematologic 
malignancies bone marrow, could be infused 
intravenously in those patients without toxicity. In 
addition, the incidence of acute and chronic GVHD 
was significantly reduced in patients co-transplanted 
with both MSCs and HSCs [21]. 
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However, the safety of MSCs co-
transplantation should be more investigated as some 
studies found that the capacity of patient Flk(+), CD3 
(-), CD34(-) MSCs to inhibit T lymphocyte activation 
and proliferation was impaired in vitro. They also 
found that CML patient-derived MSCs have impaired 
immuno-modulatory functions, suggesting that the 
dysregulation of hematopoiesis and immune response 
may originate from MSCs rather than HSCs [22]. 
In conclusion, the present study demonstrated 
that isolated MSCs from the bone marrow of patients 
with CML are negative for BCR/ABL translocation. So 
we suggest that autologous MSCs could be co-
transplanted with HSCs in CML treatment. Moreover, 
co-transplantation of allogeneic hematopoietic stem 
cells and MSCs devoid of malignant transformation 
can facilitate the implantation of hematopoietic cells & 
alleviate GVHD through their regulatory immune 
response approach. Finally, from our findings and 
similar observations by [ 2, 6, 8], it may be suggested 
that autologous MSCs can be used in this setting 
without running the risk of re-transplantation of 
leukemic stem cells. 
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